Month: August 2022

Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLC Announced successful production of personalized cancer immunotherapies for melanoma Announced gonorrhea as second bacterial product target Ended second quarter with cash and cash equivalents of $25.3 million Evaxion will host webcast and conference call today, August 10, at 8:30 am EDTCOPENHAGEN, Denmark, Aug. 10, 2022 (GLOBE NEWSWIRE) — Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today its second quarter 2022 financial results and provided an operational and business update. Lars Wegner, CEO of Evaxion, said: “Evaxion announced multiple exciting milestones in the second quarter of 2022. We expanded our DNA oncology vaccine...

BRANFORD, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) — IsoPlexis Corporation (Nasdaq: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today reported financial results for the quarter ended June 30, 2022. Recent HighlightsDrove operational efficiencies and headcount reductions through our Reduction in Force (RIF) resulting in a $4.3 million reduction in operating expenses compared to Q1 2022, representing a 14% reduction which includes $3.7 million of nonrecurring restructuring expense.Revenue of $4.0 million for the second quarter 2022, representing a 7% decrease from the corresponding period of 2021Trailing twelve months revenue of $18.7 million represents a 31% increase vs the prior year periodSold 20 new instruments in the second quarter, bringing the installed base...

Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data Safety Monitoring Board Recommended Concluding Phase 3 SHIELD I Trial of D-PLEX100 in Abdominal Soft Tissue Surgery Following Enrollment of the Minimum Number of Targeted PatientsConcluded Enrollment in Phase 3 SHIELD I TrialTop-line Results from the Phase 3 SHIELD I Trial Anticipated by End of Q3 2022Conference Call Scheduled for Today at 8:30 AM ETPETACH TIKVA, Israel, Aug. 10, 2022 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and six months ended...

HANGZHOU, China, Aug. 10, 2022 (GLOBE NEWSWIRE) — Nano Labs Ltd (Nasdaq: NA) (“we,” the “Company” or “Nano Labs”), a leading fabless integrated circuit design company and product solution provider in China, today announced its unaudited financial results as of June 30, 2022 and for the first half of 2022 then ended. First Half of 2022 Financial HighlightsNet revenue increased significantly to RMB380.1 million (US$56.6 million) from RMB22.8 million in the same period of 2021. Gross profit increased significantly to RMB176.4 million (US$26.3 million) from RMB11.2 million for the same period of 2021. Profit from operations was RMB107.6 million (US$16.0 million) for the first half of 2022, compared to a loss from operations of RMB34.2 million in the same period of 2021. Net income was RMB111.4 million (US$16.6 million) for the first...

Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update KIMMTRAK® (tebentafusp) now approved in over 30 countries with commercial launches underway in U.S. and Germany, and paid access in France Net KIMMTRAK / tebentafusp revenues of £27.7 million ($33.7 million) in Q2 2022 Transitioned all patients in Germany early access program to commercial supply in May of 2022 Protocol finalized for randomized Phase 2/3 trial of tebentafusp in advanced melanoma with first patient randomized planned for Q4 2022 Initial Phase 1 data from IMC-F106C, first PRAME x CD3 ImmTAC bispecific, accepted for oral presentation at ESMO Congress 2022 on September 9th Cash and cash equivalents of £208 million ($253 million) as of June 30, 2022. Subsequently raised £117 million ($140 million) of PIPE proceeds in July Conference call today,...

ROAD TOWN, British Virgin Islands, Aug. 10, 2022 (GLOBE NEWSWIRE) — Aura Minerals Inc. (TSX: ORA) (B3: AURA33) (“Aura” or the “Company”) announces that it has filed unaudited consolidated financial statements and management discussion and analysis (together, “Financial and Operational Results”) for the period ended June 30, 2022 (“Q2 2022”) and 2022 Guidance Update (“Guidance”). The full version of the Financial and Operational Results and the Guidance can be viewed on the Company’s website at www.auraminerals.com or on SEDAR at www.sedar.com. All amounts are in U.S. dollars unless stated otherwise. Q2 2022 Highlights (Compared to Q2 2021):Consolidated quarterly production of 55,645 of gold equivalent ounces (“GEO1”) in Q2 2022 and 121,175 GEO for the first half of 2022. Production is now expected to be in the range of between...

Mount Milligan Q2 cash provided by mine operations ($ millions) Mount Milligan Q2 cash provided by mine operations ($ millions)Mount Milligan Q2 All-in sustaining costs on a by-product basis per ounce(NG) ($/oz) Mount Milligan Q2 All-in sustaining costs on a by-product basis per ounce(NG) ($/oz)Mount Milligan YTD cash provided by mine operations ($ millions) Mount Milligan YTD cash provided by mine operations ($ millions)Mount Milligan YTD All-in sustaining costs on a by-product basis per ounce(NG) ($/oz) Mount Milligan YTD All-in sustaining costs on a by-product basis per ounce(NG) ($/oz)Öksüt Mine Q2 cash (used in) provided by mine operations ($ millions) Öksüt Mine Q2 cash (used in) provided by mine operations ($ millions)Oksut Mine YTD cash provided by mine operations ($ millions) Oksut Mine YTD cash provided by mine...

Seoul, Korea, Aug. 10, 2022 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of online and mobile games based in South Korea, today announced its unaudited financial results for the second quarter ended June 30, 2022, prepared in accordance with international Financial Reporting Standards as issued by the International Accounting Standards Board and business updates. SECOND QUARTER 2022 HIGHLIGHTSTotal revenues were KRW 96,519 million (US$ 74,305 thousand), representing an 8.9% increase from the first quarter ended March 31, 2022 (“QoQ”) and a 15.4% increase from the second quarter ended June 30, 2021 (“YoY”). Operating profit was KRW 22,115 million (US$ 17,025 thousand), representing a 0.9% decrease QoQ and a 15.4% increase YoY. Profit before income tax expenses was KRW...